Claims

1. Use of acetyl-leucine, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament, for treating a mobility disorder associated with ageing in a subject in need thereof,

wherein the subject does not have vertigo or a neurological or neurodegenerative disease, disorder or condition, and

wherein the mobility disorder associated with ageing is chosen from decreased stability, unsteadiness while walking, senile gait disorder, increase in the coefficient of variability of gait velocity or cadence, and pre-disposition to falls.

2. The use according to claim 1, wherein said acetyl-leucine is in racemate form.

3. The use according to claim 1, wherein the acetyl-leucine is to be administered in a dose ranging from 4 g to 10 g per day.

4. The use according to claim 3, wherein the acetyl-leucine is to be administered in a dose of more than 4 g to no more than 6 g per day.

5. The use according to claim 3 or 4, wherein said dose is to be administered across two or more administrations.

6. The use according to claim 5, wherein said dose is to be administered across three administrations.

7. The use according to any preceding claim, wherein the acetyl-leucine is to be administered for a treatment duration of two weeks or more.

8. The use according to claim 7, wherein the acetyl-leucine is to be administered for a treatment duration of seven weeks or more.

9. The use according to any preceding claim, wherein the acetyl-leucine is to be administered in a dose ranging from 4.5 g to 10 g per day, across three administrations per day, for a treatment duration of two months or more.